Status:
UNKNOWN
The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy
Lead Sponsor:
Hallym University Medical Center
Conditions:
Central Serous Chorioretinopathy
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antib...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of central serous chorioretinopathy
- Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
- Presence of focal leaks at the level of the RPE on fluorescein angiography
Exclusion
- Known side effects of systemic bevacizumab administration
- Have a significant cardiovascular or thromboembolic history or were pregnant
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00864773
Start Date
March 1 2009
End Date
March 1 2010
Last Update
March 19 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.